Biomedical Engineering Reference
In-Depth Information
26. Hedley DW, Chow S, Goolsby C, Shankey TV. Pharmacodynamic monitoring of
molecular-targeted agents in the peripheral blood of leukemia patients using flow
cytometry. Toxicol. Pathol. 2008;36(1):133-139.
27. CrumpM, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, et al. A randomized
phase I clinical and biologic study of two schedules of sorafenib in patients with
myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer
Institute of Canada) Clinical Trials Group Study. Leuk. Lymphoma 2010;51
(2):252-260.
28. Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib)
in phase I clinical trials involving solid tumor and AML/MDS patients, using flow
cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Cytometry B Clin. Cytom. 2006;70(3):107-114.
29. Schwock J, Ho JC, Luther E, Hedley DW, GeddieWR. Measurement of signaling pathway
activities in solid tumor fine-needle biopsies by slide-based cytometry. Diagn. Mol. Pathol.
2007;16(3):130-140.
30. Sheps JA, Ling V. Preface: the concept and consequences of multidrug resistance. Pflugers
Arch. 2007;453(5):545-553.
31. Ling V, Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs.
Cancer 1992;69(10):2603-2609.
32. Rubin EH, De Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, et al. A phase I trial of a
potent P-glycoprotein inhibitor, Zosuquidar trihydrochloride (LY335979), administered
orally in combination with doxorubicin in patients with advanced malignancies. Clin.
Cancer Res. 2002;8(12):3710-3717.
33. Darzynkiewicz Z, Crissman H, Jacobberger JW. Cytometry of the cell cycle: cycling
through history. Cytometry A 2004;58(1):21-32.
34. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. Aurora kinases
as anticancer drug targets. Clin. Cancer Res. 2008;14(6):1639-1648.
35. Vader G, Lens SM. TheAurora kinase family in cell division and cancer. Biochim. Biophys.
Acta 2008;1786(1):60-72.
36. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a
selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing
apoptosis. Clin. Cancer Res. 2007;13(12):3682-3688.
37. BlumKA, Advani A, Fernandez L, Van Der JR, Brandwein J, Kambhampati S, et al. Phase
II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated
chronic lymphocytic leukaemia. Br. J. Haematol. 2009;147(4):507-514.
38. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and
pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and
acute myeloid leukemia. Blood 2005;105(3):959-967.
39. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone
deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem.
2004;11(12):1629-43.
40. Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, et al. Phase I trial
of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors
and lymphoid malignancies. Clin. Cancer Res. 2007;13 (18 Part 1): 5411-5417.
41. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J. Clin. Oncol. 2008;26
(17):2806-2812.
Search WWH ::
Custom Search